Status:
UNKNOWN
HLA Analysis in Autoimmune Encephalitis and Related Disorders: Part II
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Autoimmune Encephalitis
Paraneoplastic Neurological Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Autoimmune encephalitis (AE) are characterized by subacute onset of memory deficits, altered mental status or psychiatric symptoms, frequently associated with seizures, inflammatory cerebrospinal flui...
Eligibility Criteria
Inclusion
- Presence of well-characterized antibodies in serum or cerebrospinal fluid;
- Clinical picture compatible with the detected antibody based on the literature;
- For PNS, cancer detected and compatible with the detected antibody based on the literature
Exclusion
- Absence of complete clinicobiological data.
- Incongruences between antibody-clinics or antibody-cancer
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT04823728
Start Date
January 1 2021
End Date
December 31 2025
Last Update
April 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Neurologique
Bron, France, 69677